Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Following Treatment with LY3439539 in Participants with Symptomatic Alzheimer’s Disease'. The following are the other relevant details related to the trial:
Therapeutic Area: Neurology
Trial Centre(s):
Lilly Centre for Clinical Pharmacology
Trial Status: NA
Principal Investigator(s):
Dr Jeffer Hann Wei Pang
Published by HT Digital Content Services with permission from Health Daily Digest....